blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3532465

EP3532465 - PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.01.2024
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  27.01.2023
FormerGrant of patent is intended
Status updated on  02.09.2022
FormerExamination is in progress
Status updated on  25.06.2021
FormerRequest for examination was made
Status updated on  02.08.2019
FormerThe international publication has been made
Status updated on  05.05.2018
Formerunknown
Status updated on  16.11.2017
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): BE		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA 94080 / US
[2019/36]
Inventor(s)01 / TSO, Kin
5000 Diamond Heights Boulevard
San Francisco, CA 94131 / US
02 / CHEN, Yan
178 Albacore Ln.
Foster City, CA 944404 / US
03 / YEN, Rose
1156 Shotwell Street
San Francisco, CA 94110 / US
04 / TAYLOR, Vanessa
564 29th Avenue
San Francisco, CA 94121 / US
05 / HECKRODT, Thilo
1918 11th Avenue
San Francisco, CA 94116 / US
06 / SINGH, Rajinder
1832 Hillman Avenue
Belmont, CA 94002 / US
07 / SHAW, Simon
1232 19th Street
Unit 10
Oakland, CA 94607 / US
08 / LI, Hui
1232 19th Street
Unit 10
Oakland, CA 94607 / US
 [2019/36]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/09]
Former [2019/36]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date17794624.125.10.2017
[2019/36]
WO2017US58329
Priority number, dateUS201662413299P26.10.2016         Original published format: US 201662413299 P
[2019/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018081294
Date:03.05.2018
Language:EN
[2018/18]
Type: A1 Application with search report 
No.:EP3532465
Date:04.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 03.05.2018 takes the place of the publication of the European patent application.
[2019/36]
Type: B1 Patent specification 
No.:EP3532465
Date:01.03.2023
Language:EN
[2023/09]
Search report(s)International search report - published on:EP03.05.2018
(Supplementary) European search report - dispatched on:EP24.06.2021
ClassificationIPC:C07D401/14, C07D405/14, C07D413/14, C07D471/04, A61K31/44, A61K31/4439, A61K31/497, A61P35/00, A61P37/02, A61P25/00, A61P9/00, A61P7/00, A61P1/00, A61P3/00, A61P11/00, A61P43/00, C07D401/12, C07D403/12, C07D403/14, A61P29/00, A61P37/00
[2021/30]
CPC:
C07D401/14 (EP,CN,US); A61K31/497 (CN); A61K31/4439 (CN);
A61K31/444 (CN); A61K31/4545 (CN); A61K31/496 (CN);
A61K31/5377 (CN); A61P1/00 (EP); A61P11/00 (EP,CN);
A61P13/12 (CN); A61P15/00 (CN); A61P25/00 (EP,CN);
A61P29/00 (EP,CN); A61P3/00 (EP); A61P31/04 (CN);
A61P31/12 (CN); A61P35/00 (EP,CN); A61P37/00 (EP);
A61P37/02 (EP,CN); A61P37/08 (CN); A61P43/00 (EP);
A61P7/00 (EP); A61P7/02 (CN); A61P7/06 (CN);
A61P9/00 (EP,CN); C07D401/12 (EP,US); C07D403/12 (EP,US);
C07D403/14 (EP,US); C07D405/14 (EP,CN,US); C07D413/14 (EP,US);
C07D471/04 (EP,CN,US) (-)
Former IPC [2019/36]C07D401/14, C07D405/14, C07D413/14, C07D471/04, A61K31/44, A61K31/4439, A61K31/497, A61P35/00, A61P37/00, A61P25/00, A61P9/00, A61P7/00, A61P1/00, A61P3/00, A61P11/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/36]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PYRAZOLAMIDVERBINDUNGEN ALS IRAK-INHIBITOREN[2019/36]
English:PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS[2019/36]
French:COMPOSÉS PYRAZOLE AMIDE EN TANT QU'INHIBITEURS D'IRAK[2019/36]
Entry into regional phase26.04.2019National basic fee paid 
26.04.2019Designation fee(s) paid 
26.04.2019Examination fee paid 
Examination procedure26.04.2019Examination requested  [2019/36]
26.04.2019Date on which the examining division has become responsible
02.12.2019Amendment by applicant (claims and/or description)
24.06.2021Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M04) [2021/30]
24.06.2021Despatch of a communication from the examining division (Time limit: M04)
21.10.2021Reply to a communication from the examining division
02.09.2022Communication of intention to grant the patent
11.01.2023Fee for grant paid
11.01.2023Fee for publishing/printing paid
11.01.2023Receipt of the translation of the claim(s)
Divisional application(s)EP23158563.9  / EP4212523
Opposition(s)04.12.2023No opposition filed within time limit [2024/06]
Fees paidRenewal fee
28.10.2019Renewal fee patent year 03
27.10.2020Renewal fee patent year 04
27.10.2021Renewal fee patent year 05
27.10.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT01.03.2023
CZ01.03.2023
DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
LU25.10.2023
BE31.10.2023
CH31.10.2023
[2024/36]
Former [2024/34]AT01.03.2023
CZ01.03.2023
DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
LU25.10.2023
CH31.10.2023
Former [2024/30]AT01.03.2023
CZ01.03.2023
DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
LU25.10.2023
Former [2024/28]AT01.03.2023
CZ01.03.2023
DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
Former [2024/10]AT01.03.2023
CZ01.03.2023
DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
Former [2023/50]AT01.03.2023
CZ01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SK01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
IS01.07.2023
PT03.07.2023
Former [2023/49]AT01.03.2023
CZ01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RO01.03.2023
RS01.03.2023
SE01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
PT03.07.2023
Former [2023/48]AT01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RS01.03.2023
SE01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
PT03.07.2023
Former [2023/46]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RS01.03.2023
SE01.03.2023
SM01.03.2023
NO01.06.2023
GR02.06.2023
PT03.07.2023
Former [2023/38]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
NL01.03.2023
PL01.03.2023
RS01.03.2023
SE01.03.2023
NO01.06.2023
GR02.06.2023
Former [2023/37]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SE01.03.2023
NO01.06.2023
GR02.06.2023
Former [2023/36]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SE01.03.2023
NO01.06.2023
Former [2023/35]HR01.03.2023
LT01.03.2023
RS01.03.2023
NO01.06.2023
Former [2023/34]LT01.03.2023
RS01.03.2023
Former [2023/33]LT01.03.2023
Cited inInternational search[A]WO2015068856  (TAKEDA PHARMACEUTICAL [JP]) [A] 1-58 * claims 1-17 * * page 1, paragraph 1 *;
 [X]WO2015069594  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-3,5,7-13,20-27,46,48-51,53 * page 207; example 205 * * claims 1-8 *;
 [IP]WO2016172560  (RIGEL PHARMACEUTICALS INC [US]) [IP] 1-58 * claims 1-75 * * page 1, lines 9-11 ** examples *
ExaminationUS2011251176
 WO2015068856
by applicantUS4738851
 US4882150
 US4921475
 US5008110
 US5077033
 US5087240
 US5088977
 US5164189
 US5163899
 US5254346
 US5290561
 US5332213
 US5336168
 US5352456
 US5403841
 US5407713
 US5521222
 US5698219
 US5776445
 US5800807
 US6056950
 US6197934
 US6261547
    - S. M. BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; V. STELLA, A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, (19870000), vol. 14
    - "General Principles", FINGL; WOODBURY, Goodman and Gilman's The Pharmaceutical Basis of Therapeutics, Pergamon Press, vol. 1, pages 1 - 46
    - TUMAS et al., J. Allergy Clin. Immunol., (20010000), vol. 107, no. 6, pages 1025 - 1033
    - SZELENYI et al., Arzneimittelforschung, (20000000), vol. 50, no. 11, pages 1037 - 42
    - KAWAGUCHI et al., Clin. Exp. Allergy, (19940000), vol. 24, no. 3, pages 238 - 244
    - SUGIMOTO et al., Immunopharmacology, (20000000), vol. 48, no. 1, pages 1 - 7
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.